CatalystFDA/Bio

Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

ESMO late-breaker selection signals pivotal Phase III overall survival data for Ivonescimab in biliary tract cancer.

What changed

ESMO late-breaker selection signals pivotal Phase III overall survival data for Ivonescimab in biliary tract cancer.

Why it matters

ESMO late-breaker selection signals pivotal Phase III overall survival data for Ivonescimab in biliary tract cancer. — impact context not separately stored; see What changed.

Sources

eodhd